CLS001
Phase 2Small molecule
CLS001 is one of 58 small molecule programs targeting Rosacea. It is currently in Phase 2.
2
Indications
5
Total Trials
0
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Rezzayo
RochePhase 3
Daliresp
AstraZenecaPhase 3
Skyrizi
AbbViePhase 3
Xyzal
CChattem
Phase 3
Flovent
PParatek Pharmaceuticals Inc
Phase 3
Rocatinlimab
AmgenPhase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
Benvitimod
PPeking University People's Hospital
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Safety and Efficacy3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CLS001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMaruho Co., Ltd.